184 related articles for article (PubMed ID: 18204432)
1. IMP-3 is a novel progression marker in malignant melanoma.
Pryor JG; Bourne PA; Yang Q; Spaulding BO; Scott GA; Xu H
Mod Pathol; 2008 Apr; 21(4):431-7. PubMed ID: 18204432
[TBL] [Abstract][Full Text] [Related]
2. IMP-3 expression in melanocytic lesions.
Yu L; Xu H; Wasco MJ; Bourne PA; Ma L
J Cutan Pathol; 2010 Mar; 37(3):316-22. PubMed ID: 19788446
[TBL] [Abstract][Full Text] [Related]
3. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions.
Yu L; Harms PW; Pouryazdanparast P; Kim DS; Ma L; Fullen DR
Mod Pathol; 2010 Sep; 23(9):1209-14. PubMed ID: 20495543
[TBL] [Abstract][Full Text] [Related]
4. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic utility of IMP3 in segregating metastatic melanoma from benign nevi in lymph nodes.
Mentrikoski MJ; Ma L; Pryor JG; McMahon LA; Yang Q; Spaulding BO; Scott GA; Wang HL; Xu H
Mod Pathol; 2009 Dec; 22(12):1582-7. PubMed ID: 19734845
[TBL] [Abstract][Full Text] [Related]
6. DEK expression in melanocytic lesions.
Kappes F; Khodadoust MS; Yu L; Kim DS; Fullen DR; Markovitz DM; Ma L
Hum Pathol; 2011 Jul; 42(7):932-8. PubMed ID: 21316078
[TBL] [Abstract][Full Text] [Related]
7. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.
Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G
Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299
[TBL] [Abstract][Full Text] [Related]
8. Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
Kantrow SM; Boyd AS; Ellis DL; Nanney LB; Richmond A; Shyr Y; Robbins JB
J Cutan Pathol; 2007 Aug; 34(8):593-6. PubMed ID: 17640227
[TBL] [Abstract][Full Text] [Related]
9. A multi-marker assay to distinguish malignant melanomas from benign nevi.
Kashani-Sabet M; Rangel J; Torabian S; Nosrati M; Simko J; Jablons DM; Moore DH; Haqq C; Miller JR; Sagebiel RW
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6268-72. PubMed ID: 19332774
[TBL] [Abstract][Full Text] [Related]
10. Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.
McBride JD; McAfee JL; Piliang M; Bergfeld WF; Fernandez AP; Ronen S; Billings SD; Ko JS
J Cutan Pathol; 2022 Mar; 49(3):220-230. PubMed ID: 34476825
[TBL] [Abstract][Full Text] [Related]
11. Spitz nevi and atypical Spitz nevi/tumors: a histologic and immunohistochemical analysis.
Kapur P; Selim MA; Roy LC; Yegappan M; Weinberg AG; Hoang MP
Mod Pathol; 2005 Feb; 18(2):197-204. PubMed ID: 15467715
[TBL] [Abstract][Full Text] [Related]
12. p16 expression: a marker of differentiation between childhood malignant melanomas and Spitz nevi.
Al Dhaybi R; Agoumi M; Gagné I; McCuaig C; Powell J; Kokta V
J Am Acad Dermatol; 2011 Aug; 65(2):357-363. PubMed ID: 21550132
[TBL] [Abstract][Full Text] [Related]
13. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
14. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
15. Expression of polycomb group protein EZH2 in nevi and melanoma.
McHugh JB; Fullen DR; Ma L; Kleer CG; Su LD
J Cutan Pathol; 2007 Aug; 34(8):597-600. PubMed ID: 17640228
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study.
Nagasaka T; Lai R; Medeiros LJ; Brynes RK; McCourty A; Harada T; Saddik M
Am J Dermatopathol; 1999 Apr; 21(2):115-20. PubMed ID: 10218669
[TBL] [Abstract][Full Text] [Related]
17. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
18. Lack of maturation with anti-leptin receptor antibody in melanoma but not in nevi.
Diwan AH; Dang SM; Prieto VG; Ellerhorst JA
Mod Pathol; 2009 Jan; 22(1):103-6. PubMed ID: 18836419
[TBL] [Abstract][Full Text] [Related]
19. The immunohistochemical profile of Spitz nevi and conventional (non-Spitzoid) melanomas: a baseline study.
Garrido-Ruiz MC; Requena L; Ortiz P; Pérez-Gómez B; Alonso SR; Peralto JL
Mod Pathol; 2010 Sep; 23(9):1215-24. PubMed ID: 20543820
[TBL] [Abstract][Full Text] [Related]
20. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
